Clinical Trial Update: A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for brentuximab vedotin in relapsed or refractory Hodgkin lymphoma, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Hodgkin Lymphoma | Phase 4 | Status: COMPLETED | Results posted: 2017-05-05